Orthocell Limited (ASX:OCC)’s stock price was down 13.7% on Thursday . The company traded as low as A$0.41 ($0.29) and last traded at A$0.41 ($0.29), approximately 6,541,784 shares changed hands during trading. The stock had previously closed at A$0.48 ($0.34).
The stock has a market capitalization of $63.28 million and a PE ratio of -8.37. The stock has a 50-day moving average of A$0.41.
About Orthocell (ASX:OCC)
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and related technologies for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and Poland. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, an autologous tenocyte implantation for chronic treatment resistant tendon injuries.
See Also: Balanced Fund
Receive News & Ratings for Orthocell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthocell and related companies with MarketBeat.com's FREE daily email newsletter.